224 related articles for article (PubMed ID: 18728627)
21. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
[TBL] [Abstract][Full Text] [Related]
22. Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir.
Guest JL; Ruffin C; Tschampa JM; DeSilva KE; Rimland D
Pharmacotherapy; 2004 Jun; 24(6):727-35. PubMed ID: 15222662
[TBL] [Abstract][Full Text] [Related]
23. Steady-state nevirapine plasma concentrations are influenced by pregnancy.
Nellen JF; Damming M; Godfried MH; Boer K; van der Ende ME; Burger DM; de Wolf F; Wit FW; Prins JM
HIV Med; 2008 Apr; 9(4):234-8. PubMed ID: 18366447
[TBL] [Abstract][Full Text] [Related]
24. Nelfinavir plasma concentrations are low during pregnancy.
Nellen JF; Schillevoort I; Wit FW; Bergshoeff AS; Godfried MH; Boer K; Lange JM; Burger DM; Prins JM
Clin Infect Dis; 2004 Sep; 39(5):736-40. PubMed ID: 15356791
[TBL] [Abstract][Full Text] [Related]
25. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
[TBL] [Abstract][Full Text] [Related]
26. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
Bonora S; Nicastri E; Calcagno A; Gonzalez de Requena D; D'Ettorre G; Sarmati L; Palmisano L; Vullo V; Di Perri G; Andreoni M
J Med Virol; 2009 Mar; 81(3):400-5. PubMed ID: 19152404
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
Bongiovanni M; Cicconi P; Landonio S; Meraviglia P; Testa L; Di Biagio A; Chiesa E; Tordato F; Bini T; Monforte Ad
Int J Antimicrob Agents; 2005 Jul; 26(1):88-91. PubMed ID: 15878262
[TBL] [Abstract][Full Text] [Related]
28. Long-term safety and effectiveness of ritonavir, nelfinavir, and lopinavir/ritonavir in antiretroviral-experienced HIV-infected children.
Rudin C; Burri M; Shen Y; Rode R; Nadal D; ;
Pediatr Infect Dis J; 2008 May; 27(5):431-7. PubMed ID: 18382386
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Podzamczer D; Ferrer E; Consiglio E; Gatell JM; Perez P; Perez JL; Luna E; González A; Pedrol E; Lozano L; Ocaña I; Llibre JM; Casiró A; Aranda M; Barrufet P; Martínez-Lacasa J; Miró JM; Badía X; Casado A; Lupo S; Cahn P; Maños M; Estela J
Antivir Ther; 2002 Jun; 7(2):81-90. PubMed ID: 12212928
[TBL] [Abstract][Full Text] [Related]
31. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
[TBL] [Abstract][Full Text] [Related]
32. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.
DiCenzo R; DiFrancesco R; Cruttenden K; Donnelly J; Schifitto G
Ann Pharmacother; 2009 Dec; 43(12):1972-7. PubMed ID: 19934383
[TBL] [Abstract][Full Text] [Related]
33. Are plasma levels valid surrogates for cellular concentrations of antiretroviral drugs in HIV-infected patients?
Colombo S; Telenti A; Buclin T; Furrer H; Lee BL; Biollaz J; Decosterd LA;
Ther Drug Monit; 2006 Jun; 28(3):332-8. PubMed ID: 16778716
[TBL] [Abstract][Full Text] [Related]
34. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
[TBL] [Abstract][Full Text] [Related]
35. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations.
Lafeuillade A; Solas C; Halfon P; Chadapaud S; Hittinger G; Lacarelle B
HIV Clin Trials; 2002; 3(1):27-35. PubMed ID: 11819183
[TBL] [Abstract][Full Text] [Related]
36. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
[TBL] [Abstract][Full Text] [Related]
37. Nevirapine-associated toxicity in HIV-infected Thai men and women, including pregnant women.
Phanuphak N; Apornpong T; Teeratakulpisarn S; Chaithongwongwatthana S; Taweepolcharoen C; Mangclaviraj S; Limpongsanurak S; Jadwattanakul T; Eiamapichart P; Luesomboon W; Apisarnthanarak A; Kamudhamas A; Tangsathapornpong A; Vitavasiri C; Singhakowinta N; Attakornwattana V; Kriengsinyot R; Methajittiphun P; Chunloy K; Preetiyathorn W; Aumchantr T; Toro P; Abrams EJ; El-Sadr W; Phanuphak P
HIV Med; 2007 Sep; 8(6):357-66. PubMed ID: 17661843
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of lopinavir/ritonavir versus nelfinavir as the first-line highly active antiretroviral therapy regimen for HIV infection.
Simpson KN; Luo MP; Chumney E; Sun E; Brun S; Ashraf T
HIV Clin Trials; 2004; 5(5):294-304. PubMed ID: 15562370
[TBL] [Abstract][Full Text] [Related]
39. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
40. Thai HIV-1-infected women do not require a dose increase of lopinavir/ritonavir during the third trimester of pregnancy.
Ramautarsing RA; van der Lugt J; Gorowara M; Kerr SJ; Burger D; Ruxrungtham K; Phanuphak P; Chaithongwongwatthana S; Avihingsanon A; Phanuphak N
AIDS; 2011 Jun; 25(10):1299-303. PubMed ID: 21516029
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
